Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the fourth quarter and year ended December 31, 2012 and disclosed its primary objectives for 2013.
Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, â€śDuring the past three years, we have successfully established one of the most impressive discovery pipelines in the biopharma industry. This accomplishment has both validated our long-term research commitment to the creation of a unique predictive discovery infrastructure and provided the Company with broad opportunities for initial commercialization and ongoing growth. Accordingly, included in our objectives for 2013 are the following:
Martin Gerstel, chairman of Compugen, added, â€śOur primary corporate objectives for 2013 clearly demonstrate that this past year represented an important inflection point for our Company. During 2012, the first wave of therapeutic product candidates in our Pipeline Program successfully reached the stage where we now have the ability to choose, on a product by product basis, which products should move forward under early stage commercialization and licensing arrangements, and which should continue to be developed through initial human clinical trials on our own. In this regard, the high level of interest being expressed by leading companies in the industry as we now pursue possible collaboration arrangements provides us with further confirmation and confidence with respect to the potential medical and commercial value of these product candidates and the power of our unique predictive discovery capabilities."
Compugenâ€™s net loss for calendar 2012 was $13.6 million (after reflecting non-cash items of $3.1 million consisting of an expense of $2.5 million related to stock based compensation and a non-cash financial loss of $588,000 related to the accounting for certain research and development funding arrangements), or $0.38 per share, compared with a net loss of $12.0 million (after reflecting non-cash items of $3.5 million consisting of an expense of $3.4 million related to stock based compensation and a non-cash financial loss of $113,000 related to the accounting for certain research and development funding arrangements), or $0.35 per share, for 2011. The increase in net loss for calendar 2012, compared with the same period in 2011, resulted in large part from increased research and development expenses, net, as further discussed below.
Research and development expenses, net, for the fourth quarter of 2012 were $2.6 million, compared with $1.9 million for the fourth quarter of 2011, and remained the Companyâ€™s largest expense. Research and development expenses, net, for calendar 2012 were $9.4 million, compared with $6.8 million for 2011. The growth in research and development expenses, net, for the fourth quarter and full year, reflects establishment and initiation of activities at the South San Francisco operation as well as increasing levels of activity in support of the Companyâ€™s Pipeline Program, and a decrease in governmental and other grants, which are deducted from research and development expenses in calculating research and development expenses, net.
As of December 31, 2012 and 2011, the liability related to the "Research and development funding arrangements and others" amounted to $7.9 million and $6.4 million, respectively, resulting from the accounting for the Baize research and development funding arrangements signed in December 2011 and December 2010. The liability balances are primarily related to the estimated fair values of the embedded derivative instruments resulting from the right of the investor, under both arrangements, to waive its right to receive potential future payments in exchange for Compugen ordinary shares.
As of December 31, 2012, cash and cash related accounts totaled $19.6Â million compared with $22.4 million at December 31, 2011, representing a net decrease in cash and cash related accounts of $2.8 million for calendar year 2012. For calendar year 2013, Compugen anticipates gross cash expenditures of approximately $16 million, compared with gross cash expenditures of approximately $13 million for calendar 2012, without taking into account any revenues or other cash sources in either year. With respect to such revenues and other cash sources, Compugen currently anticipates the total such amount to be received during 2013 to be at least equal to the total amount received in 2012. The cash and cash related accounts at both December 31, 2012 and December 31, 2011 do not include the market value of Compugenâ€™s holdings of Evogene shares on such dates and the final installment due to Compugen at the end of April 2013 under the December 2011 Baize research and development funding arrangement, as amended.
Conference Call and Webcast Information
Compugen will hold a conference call to discuss its fourth quarter and yearend results today, February 20, 2013 at 10:00 a.m. EST. To access the conference call, please dial 1-888-668-9141 from the US or +972-3-918-0609 internationally. The call will also be available via live webcast through Compugenâ€™s website, located at the following link.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or +972-3-925-5904 internationally. The replay will be available through February 23, 2013.
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for theÂ in silicoÂ (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.
This press release contains â€śforward-looking statementsâ€ť within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which include Compugenâ€™s corporate objectives and expectations regarding revenues and other cash sources for 2013, include words such as â€śmay,â€ť â€śexpects,â€ť â€śanticipates,â€ť â€śbelieves,â€ť and â€śintends,â€ť and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are discussed in the "Risk Factors" section of Compugenâ€™s Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugenâ€™s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
(U.S. dollars in thousands, except for share and per-share amounts)
Three Months EndedDecember 31,
Year EndedDecember 31,
|Cost of revenues*||168||-||201||-|
|Gross profit (loss)||(34||)||-||41||-|
|Research and development expenses, net||2,608||1,854||9,442||6,778|
|Marketing and business development expenses||186||114||684||610|
|General and administrative expenses||1,013||1,102||3,457||4,591|
Total operating expenses**
Financing loss, net***
|Basic and diluted net loss per ordinary share||(0.15||)||(0.13||)||(0.38||)||(0.35||)|
Weighted average number of Ordinary shares used in computing basic net loss per share
Weighted average number of Ordinary shares used in computing diluted net loss per share
* Three months ended December 31, 2012 amount reflects an adjustment from prior quarter; all amounts include non-cash stock based compensation.
** Includes non-cash stock based compensation.
*** Includes non-cash loss due to required periodic re-measurement of fair value of exchange option and embedded derivatives within research and development arrangements of approximately $1,843 and $588 for the most recent quarter and for the year ended December 31, 2012, respectively, and $906 and $113 for the comparable periods of 2011.
|CONDENSED CONSOLIDATED BALANCE SHEETS DATA|
(U.S. dollars, in thousands)
|Cash, cash equivalents and short-term bank deposits||19,589||22,371|
|Investment in Evogene||5,196||-|
|Accounts receivables and prepaid expenses||690||546|
|Total current assets||25,571||23,009|
|Investment in Evogene||-||4,093|
|Long-term lease deposits||59||17|
|Severance pay fund||1,728||1,465|
|Total non-current investments||1,787||5,575|
|Long-term prepaid expenses||301||-|
|Property and equipment, net||1,250||497|
|LIABILITIES AND SHAREHOLDERSâ€™ EQUITY|
|Accounts payable and accrued expenses||1,384||1,423|
|Total current liabilities||1,384||1,423|
|Research and development funding arrangements and others||7,872||6,434|
|Accrued severance pay||1,981||1,643|
|Total non-current liabilities||9,853||8,077|
|Total shareholdersâ€™ equity||17,672||19,581|
|Total liabilities and shareholdersâ€™ equity||28,909||29,081|
Last updated on: 20/02/2013